Table 1– A comparison of demographic and clinical data between ILD of SSc and IPF patients
Subjects n16897
Age yrs49.5±13.263.7±8.8<0.00005
Males/females n31/13773/24<0.0005
Never-/ex-smokers n108/6017/80<0.0005
Deaths60/168 (36)84/97 (87)<0.0005
 5-yr survival %7618
Patients with FVC decline87/152 (57)63/89 (71)<0.05
 Median time to decline months5711
Patients with DL,CO decline88/152 (58)61/89 (69)0.10
 Median time to decline months6211
Patients with PFS32/152 (21)6/89 (7)<0.005
 Median time to decline months3610
FVC % pred78.2±21.567.8±20.6<0.0005
DL,CO % pred55.4±17.036.9±14.7<0.00005
HRCT disease extent %13.3 (1.0–84.0)56.5 (8.5–96.0)<0.00005
  • Data are presented as mean±sd , n/N (%) or median (range), unless otherwise stated. SSc: systemic sclerosis; ILD: interstitidl lung disease; IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity; DL,CO: diffusing capacity of the lung for carbon monoxide; PFS: progression-free survival; % pred: % predicted; CPI: composite physiologic index; HRCT: high-resolution computed tomography.